<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701490</url>
  </required_header>
  <id_info>
    <org_study_id>18E-Prg06</org_study_id>
    <nct_id>NCT03701490</nct_id>
  </id_info>
  <brief_title>Prolutex in Frozen Embryo Transfer Cycles at the Blastocyst Stage (PROGEX)</brief_title>
  <acronym>PROGEX</acronym>
  <official_title>A Proof of Concept, Randomized, Controlled Clinical Trial to Assess the Efficacy of Subcutaneous Progesterone (Prolutex) Versus Vaginal Progesterone (Progeffik) for Endometrial Preparation in Women Undergoing Frozen Embryo Transfer(FET) Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this proof of concept clinical trial is to evaluate the impact of two
      different progesterone treatments for endometrial preparation (25 mg/twice-a-day,
      subcutaneous injection, and 200 mg/three times a day, vaginal administration) on the clinical
      pregnancy rate in women undergoing frozen embryo transfer (FET) at blastocyst stage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>4-5 weeks after progesterone treatment start.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum progesterone level</measure>
    <time_frame>19+/-2 days and 4-5 weeks after start progesterone treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of uterine contractions</measure>
    <time_frame>on the day of Embryo transfer (i.e. 5 days after start progesterone treatment)</time_frame>
    <description>n of uterine contraction/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive serum pregnancy (beta-hCG) test rate</measure>
    <time_frame>19+/-2 days after start progesterone treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>4-5 weeks after start progesterone treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>9-11 weeks after start progesterone treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abortion rate</measure>
    <time_frame>9 months after start progesterone treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Prolutex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Progeffik</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone subcutaneous</intervention_name>
    <description>25 mg/twice a day.</description>
    <arm_group_label>Prolutex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone Vaginal Product</intervention_name>
    <description>200 mg three times a day.</description>
    <arm_group_label>Progeffik</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women attending the clinics to undergo a frozen blastocyst embryo transfer, having
             given written informed consent, with the following characteristics:

          -  18-49 years of age for subjects undergoing ET with donated oocytes (both inclusive);

          -  18-37 years of age for subjects undergoing ET with autologous oocytes (both
             inclusive);

          -  BMI &lt;32 kg/m2;

          -  Adequate endometrium preparation (Endometrial thickness &gt; 7 mm) and E2 levels ( &gt;100
             pg/ml) on the day progesterone treatment is started;

          -  P4 levels &lt;1.5 ng/ml on the day progesterone treatment is started;

          -  Transfer of 1 or 2 frozen embryos at blastocyst stage

          -  Transfer of frozen embryos of quality A and/or B according to Gardner criteria1;

          -  Semen from ejaculation either from the partner or from a bank

          -  ≤ 3 previous ET (frozen and fresh) with no pregnancy

          -  Normal uterine cavity (i.e. no polyp or protruding sub-mucosal fibroid).

        Exclusion Criteria:

          -  Presence of functional follicles &gt; 10 mm of diameter on the day progesterone treatment
             is started;

          -  Intramural uterine fibroids that distort the uterine cavity or polyps &gt;1 cm;

          -  Stage III or IV endometriosis (endometriomas);

          -  Hydrosalpinx;

          -  Pregnancy or lactation

          -  Malformations of the sexual organs incompatible with pregnancy;

          -  Patients affected by pathologies associated with any contraindication of being
             pregnant;

          -  Known allergy to progesterone preparations or their excipients;

          -  Uncontrolled adrenal or thyroid dysfunction;

          -  Undiagnosed vaginal haemorrhage;

          -  History of, or current arterial disease;

          -  Patients with hepatic impairment;

          -  HIV, Hepatitis B Virus or Hepatitis C Virus seropositive;

          -  Neoplasias (current) or history of neoplasia that may be responsive to progesterone;

          -  High grade cervical dysplasia;

          -  Active thrombophlebitis or thromboembolic disorders, or a history of
             hormone-associated thrombophlebitis or thromboembolic disorders;

          -  Currently dependent on alcohol, drugs or psychotropic drugs

          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages
             wherein pregnancy developed to a minimum of a gestational sac on transvaginal
             ultrasonography;

          -  Participation in a concurrent clinical trial or another trial within the past 2
             months;

          -  Use of concomitant medications that might interfere with the study evaluation:
             hormonal treatments other than those used in the study, except thyroid hormones.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquín Llácer, MD</last_name>
      <phone>+34 965 154 000</phone>
      <email>jllacer@institutobernabeu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ginemed</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascual Sánchez, MD</last_name>
      <phone>+34 954 991 051</phone>
      <email>psanchez@ginemed.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

